MEMPHIS, Tenn.--(BUSINESS WIRE)--An international collaboration between Vaxent, a Memphis-based early stage vaccine development company in the Memphis Bioworks Foundation Incubator, and The Pan-Provincial Vaccine Enterprise Inc. (PREVENT), a Centre of Excellence for Commercialization and Research (CECR) in Saskatchewan, has put a vaccine for group A streptococcus (Strep-A) back on the path for potential commercialization. Under the terms of the agreement, PREVENT receives the exclusive worldwide license to progress vaccine candidates through developing vaccine formulations, manufacturing, completing preclinical studies and conducting clinical trials. Both parties will participate in the commercialization process under a cost-sharing and revenue-sharing arrangement.
